SABCS 2014

Adjuvant Bisphosphonates: Winner in Postmenopausal Breast Cancer

Phoebe Starr

February 2014, Vol 5, No 1 - SABCS 2014

San Antonio, TX—Adjuvant bisphosphonates reduce the risk of bone metastases by approximately 33% and improve breast cancer–related survival by 17% in postmenopausal women with early breast cancer, according to a large meta-analysis reported at the 2013 San Antonio Breast Cancer Symposium (SABCS). Bisphosphonates had no effect on premenopausal women in the adjuvant setting.

[ Read More ]

Aromatase Inhibitor–Related Pain Reduced with Exercise Regimen

Charles Bankhead

February 2014, Vol 5, No 1 - SABCS 2014

San Antonio, TX—Breast cancer survivors obtained significant relief from aromatase inhibitor–associated joint pain with a prescribed exercise program, the results of a randomized clinical trial showed.

At the end of 1 year, the patients in the exercise group reported 20% to 30% less pain compared with a control group that was randomized to usual care. The benefits were consistent across subgroups, irrespective of age, disease stage, treatment regimen, or duration of aromatase inhibi­­-
t­or therapy.

[ Read More ]